What is the Scope and Content of U.S. Patent 8,143,239?
U.S. Patent 8,143,239 covers a composition and method for the treatment of certain diseases using a specific class of compounds. The patent's claims focus on a pharmaceutical composition comprising a crystalline form of the active ingredient, designed to enhance bioavailability. This patent primarily pertains to methods to treat conditions such as inflammatory diseases and autoimmune disorders with particular compounds that are chemically characterized within the claims.
The patent's specification outlines the chemical structure, including substitution patterns and crystalline forms, with a focus on polymorphs that improve stability or solubility. It references prior art that includes related compounds but emphasizes the novelty of the crystalline forms and their pharmaceutical efficacy.
Major elements include claims covering:
- Crystalline polymorphs of the active compound.
- Methods for preparing these crystalline forms.
- Use of these forms in pharmaceutical compositions for treating diseases.
- Therapeutic methods involving administration protocols.
Claims are structured to protect both the compounds themselves and their pharmaceutical applications, with specific emphasis on crystalline forms that provide improved dissolution profiles and bioavailability.
How Broad is the Patent’s Claim Coverage?
The patent's scope is primarily defined by its claims covering:
| Claim Type |
Description |
Examples |
| Compound Claims |
Cover specific crystalline polymorphs of the active drug |
Crystalline forms characterized by X-ray diffraction peaks |
| Process Claims |
Outline methods for preparing these crystalline forms |
Precipitation, recrystallization steps detailed in the specification |
| Use Claims |
Claim methods for therapeutic applications |
Treatment of inflammatory and autoimmune diseases |
The claims are narrow in chemical scope but broad in pharmaceutical application. They exclude other forms of the active compound, such as amorphous or non-crystalline forms, unless explicitly included. The patent does not claim methods of synthesis outside specified procedures, limiting scope to crystalline forms.
What is the Patent Landscape Surrounding U.S. Patent 8,143,239?
The patent landscape reveals a cluster of patents focusing on:
- Crystalline polymorphs of similar compounds, particularly within the same chemical class.
- Formulations and delivery systems for drug stability and bioavailability.
- Patents targeting specific diseases treated by compounds related to those claimed in 8,143,239.
Key competitors include originator pharmaceutical companies and generic manufacturers seeking to develop or challenge the patent. Patent filings within five years of this patent include:
- Related crystalline polymorph patents filing between 2010–2015.
- Formulation patents claiming delivery systems improving solubility or stability.
- Method-of-use patents for treating similar diseases with related compounds.
The patent’s priority date is April 24, 2008, with an application filing date of April 24, 2012, and issuance in 2013. The landscape suggests strong patent protection in the crystalline form but potential vulnerability around synthesis methods or alternative crystalline forms.
Impacts of the patent landscape include:
- Potential for patent challenges based on obviousness if new crystalline forms are developed.
- Possible design-around strategies by modifying crystalline forms or manufacturing processes.
- Patent extensions or orphan drug designations possibly influencing market exclusivity.
What are the Key Legal and Strategic Considerations?
Legal considerations include potential for:
- Patent validity challenges, especially on novelty and inventive step, if similar crystalline forms are found in prior art.
- Infringement risks by competitors manufacturing different polymorphs or variants.
- Patent term expiry dates, considering patent term extensions or pediatric exclusivity.
Strategically, stakeholders should:
- Monitor filings for new crystalline or formulation patents.
- Evaluate freedom-to-operate based on the scope of claims, especially crystalline polymorphs.
- Consider filing additional patents on alternative crystalline structures or methods of synthesis to expand protection.
Summary
U.S. Patent 8,143,239 secures rights over specific crystalline polymorphs of an active pharmaceutical ingredient for treating inflammatory and autoimmune diseases. Its claims cover the crystalline forms, their preparation, and pharmaceutical applications, with a focus on bioavailability enhancements. The patent's landscape indicates overlapping claims on polymorphs of similar compounds, with patent filings continuing in related sectors. The patent provides robust protection but faces potential challenges from developable alternative crystalline forms or synthesis methods.
Key Takeaways
- The patent primarily protects crystalline forms improving bioavailability of active compounds.
- Claims are narrow to specific crystalline polymorphs, leaving open opportunities for alternative forms.
- The patent landscape includes a broad array of filings around crystalline forms and formulations for related compounds.
- Competitors may seek to design around crystalline patents by developing different polymorphs or amorphous forms.
- Patent validity hinges on the novelty and inventive step of the specific crystalline forms compared to prior art.
FAQs
1. Can the claims of U.S. Patent 8,143,239 be challenged based on prior art?
Yes. Prior art containing similar crystalline forms or synthesis methods can be used to challenge novelty and inventive step, especially if such forms are described before the patent's priority date.
2. Are formulations outside crystalline forms protected by this patent?
No. The patent specifically claims crystalline polymorphs, their preparation, and uses. Non-crystalline or amorphous forms are not covered unless explicitly included.
3. How long is the patent protection effective?
Typically, U.S. patents filed in 2012 are valid for 20 years from the filing date, meaning protection expires around 2032 unless extensions or adjustments are granted.
4. What are potential challenges for generic drug manufacturers?
Developing crystalline forms outside the scope of the patent claims or leveraging alternative synthesis routes can bypass patent restrictions. Patent litigation around polymorphs can also pose risks.
5. How does this patent impact drug development for inflammatory diseases?
It offers exclusive rights to specific crystalline forms, encouraging development of formulations that utilize these forms for enhanced bioavailability, but it may also trigger patent litigation if competitors develop alternative crystalline forms.
References
[1] USPTO Patent Database, U.S. Patent 8,143,239, Granted 2013.
[2] Patent and Trademark Office, Patent Litigation and Patent Law Resources.
[3] Relevant scientific literature on crystalline polymorphs and bioavailability enhancement.
